UPDATE - RTI Outlook and Analysis RTI Outlook and Analysis Radient's has three competitive advantages that make it a standout investment opportunity. First, Radient has world-class expertise in extracting more actives from plants and significantly increase the yields and purity at lower costs compared with competitive extraction technologies. Second, because of the favorable regulation in Canada and its unique positioning, Radient has requested proper accreditation and permits from the Canadian Government for conducting research and the eventual commercial production of standardized cannabinoids extracts. Last and perhaps foremost, Radient is already partnering with researchers, growers and companies having complementary skills to advance its leadership and establish itself as a North America leader in the development of standardized cannabinoid extracts from both marijuana and hemp. To that end, in December the company signed a memorandum of understanding with Aurora Cannabis to evaluate an exclusive partnership for the Canadian market with regard to the joint development and commercialization of superior and standardized cannabinoid extracts. As part of the MOU, Aurora will, subject to certain conditions precedent being satisfied, invest up to $2 million into Radient by means of a convertible debenture. Aurora, one of the largest licensed producers of medical cannabis under Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR), recently began construction on an unprecedented 800,000 square foot production facility in Leduc County, Alberta. This facility, known as "Aurora Sky", is anticipated to be capable of producing in excess of 100,000 kg of high-quality, lowcost marijuana per year. Denis Taschuk, President and CEO of Radient, explained "We are very excited by this potential partnership with Aurora, given their leadership position in the medical cannabis space and the exceptional quality of their products. The combination of Aurora's recently announced capacity expansion with our proprietary high-throughput extraction technology has the potential to play an important role in meeting the fast-growing demand for quality cannabinoid extracts." It's a significant milestone, and a compelling opportunity in light of the ongoing acceptance and legalization of cannabinoids for a variety of uses. It may also mark the beginning of many more such partnerships that add incremental revenue. At stake is a piece of a cannabinoid market that could be worth $20 billion by 2020, and is not only currently underserved, but currently lacks any real scientific innovation that allows for large-scale, consumer-grade product creation. In other words, the cannabinoid business isn't treated like a Fortune 500 opportunity by even its biggest players. Radient not only has a chance to change that with a better, large-scale extraction science, but in so doing it's well positioned to become the dominant player in the space. On that note, what any current or prospective RTI shareholders must absolutely embrace is that Radient is already doing business by supplying all sorts of ingredients to major companies using its M.A.P. technologies. Those products and market may not total up to the potential revenue cannabinoids represent for Radient, but the company can be viewed as self-funding, driving revenue right now with existing product lines that can be invested in its enormous cannabisbased opportunity. That near-term/long-term value/growth duality is a characteristic rarely seen among micro cap stocks, which makes RTI just that much more compelling.
https://static.viame.com/public_files/Radient-Technologies-Research-Report/2016/12/21/a21e43595643f8a8690ef96a8350f46f/RTI+Report.pdf